Hcw Biologics INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: HCW Biologics CEO Dr. Hing C. Wong Boosts Stake to 23.38% Through Strategic Debt-to-Equity Conversions
Dr. Hing C. Wong, Founder and CEO of HCW Biologics Inc., has significantly increased his beneficial ownership to 23.38% of the company's common stock by converting secured and unsecured notes into equity, a move aimed at strengthening the balance sheet.